Categories
October Surprise 2024

Breast-Oncology Clinical Trials – University of California, Irvine

Locally advanced or metastatic HER2-positive or HER2-low (IHC1+/IHC2+, HER2-negative) breast cancer. Must have progression during or after the most recent treatment for advanced/metastatic cancer. No prior treatment with anti-CD47 or SIRP-alpha agent. If brain metastasis is present, disease must be stable.